The SPC blog

A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Monday, 30 June 2014

Navarra court upholds Spanish Telmisartan + hctz invalidity ruling

Almost two years ago to the day, The SPC Blog reported on the fate of the unhappy fate of the SPC for Telmisartan + hctz in Spain (see "Telmisartan + hctz: combination SPC revoked in Spain", 26 June 2012, here, and "Telmisartan + hctz: combination SPC in Spain -- now in English" (8 July 2012, here.

This decision, invalidating the SPC, has now been upheld on appeal: see "Navarra Court of Appeal confirms invalidity of Spanish SPC for telmisartan + hctz", written for today's International Law Office release by Sara Pelaz (Grau & Angulo), here. This helpful note adds that Boehringer still has the option of lodging an appeal with the Spanish Supreme Court.

Posted by Jeremy at 10:18 am
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)